195 related articles for article (PubMed ID: 2952810)
1. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
[TBL] [Abstract][Full Text] [Related]
2. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Schulze H; Senge T
J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
[TBL] [Abstract][Full Text] [Related]
3. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
Boccon-Gibod L; Laudat MH; Dugue MA; Steg A
Eur Urol; 1986; 12(6):400-2. PubMed ID: 2949980
[TBL] [Abstract][Full Text] [Related]
4. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM
Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
[TBL] [Abstract][Full Text] [Related]
5. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
6. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
[TBL] [Abstract][Full Text] [Related]
7. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
Allen JM; Williams G; O'Shea JP; Smith C; Yeo T; Kerle D; Bloom SR
Urol Res; 1984; 12(5):249-51. PubMed ID: 6240150
[TBL] [Abstract][Full Text] [Related]
8. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F; Serio M; D'Eramo G; Sciarra F
Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
[TBL] [Abstract][Full Text] [Related]
9. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
de Voogt HJ; Klijn JG; Studer U; Schröder F; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):965-9. PubMed ID: 2149509
[TBL] [Abstract][Full Text] [Related]
10. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Waxman J; Williams G; Sandow J; Hewitt G; Abel P; Farah N; Fleming J; Cox J; O'Donoghue EP; Sikora K
Am J Clin Oncol; 1988; 11 Suppl 2():S152-5. PubMed ID: 2853934
[TBL] [Abstract][Full Text] [Related]
11. Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects.
Huhtaniemi I; Parvinen M; Venho P; Rannikko S
Int J Androl; 1991 Oct; 14(5):374-86. PubMed ID: 1839022
[TBL] [Abstract][Full Text] [Related]
12. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
[TBL] [Abstract][Full Text] [Related]
13. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
Borgmann V; al-Abadi H; Nagel R
Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
[TBL] [Abstract][Full Text] [Related]
14. Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.
Paisey RB; Kadow C; Bolton C; Hartog M; Gingell JC
J R Soc Med; 1986 Apr; 79(4):210-1. PubMed ID: 2939240
[TBL] [Abstract][Full Text] [Related]
15. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
Klijn JG; de Voogt HJ; Studer UE; Schröder FH; Sylvester R; De Pauw M
Cancer; 1993 Dec; 72(12 Suppl):3858-62. PubMed ID: 8252504
[TBL] [Abstract][Full Text] [Related]
16. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters.
Bosch RJ; Griffiths DJ; Blom JH; Schroeder FH
J Urol; 1989 Jan; 141(1):68-72. PubMed ID: 2462067
[TBL] [Abstract][Full Text] [Related]
17. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
Varenhorst E; Wallentin L; Carlström K
Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
[TBL] [Abstract][Full Text] [Related]
18. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
Di Silverio F; Sciarra F; D'Eramo G
Eur Urol; 1990; 18(1):10-5. PubMed ID: 2144819
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment in M1 prostate cancer.
Ferrari P; Castagnetti G; Ferrari G; Pollastri CA; Tavoni F; Dotti A
Cancer; 1993 Dec; 72(12 Suppl):3880-5. PubMed ID: 8252509
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]